139 related articles for article (PubMed ID: 27552291)
1. VIGABATRIN TOXICITY IN INFANCY IS ASSOCIATED WITH RETINAL DEFECT IN ADOLESCENCE: A Prospective Observational Study.
Wright T; Kumarappah A; Stavropoulos A; Reginald A; Buncic JR; Westall CA
Retina; 2017 May; 37(5):858-866. PubMed ID: 27552291
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication.
Kjellström U; Andréasson S; Ponjavic V
Acta Ophthalmol; 2014 Mar; 92(2):149-57. PubMed ID: 23387307
[TBL] [Abstract][Full Text] [Related]
3. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
[TBL] [Abstract][Full Text] [Related]
4. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
Lawthom C; Smith PE; Wild JM
Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
[TBL] [Abstract][Full Text] [Related]
5. Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study.
Westall CA; Wright T; Cortese F; Kumarappah A; Snead OC; Buncic JR
Neurology; 2014 Dec; 83(24):2262-8. PubMed ID: 25381295
[TBL] [Abstract][Full Text] [Related]
6. Vigabatrin effect on inner retinal function.
Coupland SG; Zackon DH; Leonard BC; Ross TM
Ophthalmology; 2001 Aug; 108(8):1493-6; discussion 1497-8. PubMed ID: 11470707
[TBL] [Abstract][Full Text] [Related]
7. Optical coherence tomography to monitor vigabatrin toxicity in children.
Origlieri C; Geddie B; Karwoski B; Berl MM; Elling N; McClintock W; Alexander J; Bazemore M; de Beaufort H; Hutcheson K; Miller M; Taylormoore J; Jaafar MS; Madigan W
J AAPOS; 2016 Apr; 20(2):136-40. PubMed ID: 27079594
[TBL] [Abstract][Full Text] [Related]
8. Electroretinographic (ERG) responses in pediatric patients using vigabatrin.
Moskowitz A; Hansen RM; Eklund SE; Fulton AB
Doc Ophthalmol; 2012 Jun; 124(3):197-209. PubMed ID: 22426576
[TBL] [Abstract][Full Text] [Related]
9. Vigabatrin-associated visual field defects in children.
Russell-Eggitt IM; Mackey DA; Taylor DS; Timms C; Walker JW
Eye (Lond); 2000 Jun; 14 ( Pt 3A)():334-9. PubMed ID: 11026995
[TBL] [Abstract][Full Text] [Related]
10. Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.
Durbin S; Mirabella G; Buncic JR; Westall CA
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):4011-6. PubMed ID: 19279311
[TBL] [Abstract][Full Text] [Related]
11. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss.
Harding GF; Wild JM; Robertson KA; Rietbrock S; Martinez C
Neurology; 2000 Aug; 55(3):347-52. PubMed ID: 10932265
[TBL] [Abstract][Full Text] [Related]
12. Retinal nerve fiber layer thickness in vigabatrin-exposed patients.
Clayton LM; Dévilé M; Punte T; Kallis C; de Haan GJ; Sander JW; Acheson J; Sisodiya SM
Ann Neurol; 2011 May; 69(5):845-54. PubMed ID: 21246602
[TBL] [Abstract][Full Text] [Related]
13. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer.
Wild JM; Robson CR; Jones AL; Cunliffe IA; Smith PE
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):917-24. PubMed ID: 16505024
[TBL] [Abstract][Full Text] [Related]
14. Reduction of retinal nerve fiber layer thickness in vigabatrin-exposed patients: A meta-analysis.
Peng Y; Zhao Y; Hu W; Hu Y; He Y; Zhou Y
Clin Neurol Neurosurg; 2017 Jun; 157():70-75. PubMed ID: 28412542
[TBL] [Abstract][Full Text] [Related]
15. Changes in the ERG d-wave with vigabatrin treatment in a pediatric cohort.
Dragas R; Westall C; Wright T
Doc Ophthalmol; 2014 Oct; 129(2):97-104. PubMed ID: 25008578
[TBL] [Abstract][Full Text] [Related]
16. Patterns of peripapillary retinal nerve fiber layer thinning in vigabatrin-exposed individuals.
Clayton LM; Devile M; Punte T; de Haan GJ; Sander JW; Acheson JF; Sisodiya SM
Ophthalmology; 2012 Oct; 119(10):2152-60. PubMed ID: 22853973
[TBL] [Abstract][Full Text] [Related]
17. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.
Kinirons P; Cavalleri GL; O'Rourke D; Doherty CP; Reid I; Logan P; Liggan B; Delanty N
Epilepsia; 2006 Feb; 47(2):311-7. PubMed ID: 16499754
[TBL] [Abstract][Full Text] [Related]
18. Vigabatrin-Induced Retinal Functional Alterations and Second-Order Neuron Plasticity in C57BL/6J Mice.
Chan K; Hoon M; Pattnaik BR; Ver Hoeve JN; Wahlgren B; Gloe S; Williams J; Wetherbee B; Kiland JA; Vogel KR; Jansen E; Salomons G; Walters D; Roullet JB; Gibson KM; McLellan GJ
Invest Ophthalmol Vis Sci; 2020 Feb; 61(2):17. PubMed ID: 32053727
[TBL] [Abstract][Full Text] [Related]
19. Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin?
Conway ML; Hosking SL; Zhu H; Cubbidge RP
BMC Ophthalmol; 2014 Dec; 14():166. PubMed ID: 25539569
[TBL] [Abstract][Full Text] [Related]
20. Visual fields in young children treated with vigabatrin.
Agrawal S; Mayer DL; Hansen RM; Fulton AB
Optom Vis Sci; 2009 Jun; 86(6):767-73. PubMed ID: 19417698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
